Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1407-1416

  Watanabe, Mamoru ^a   Hibi, Toshifumi ^b   Mostafa, Nael M ^c   Chao, Jingdong ^c   Arora, Vipin ^c   Camez, Anne ^c   Petersson, Joel ^c   Thakkar, Roopal ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c ABBVIE INC   (United States)

Author keywords

Adalimumab; Crohn's disease; Japan; Long term; Maintenance

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; GAMMA GLUTAMYLTRANSFERASE; MERCAPTOPURINE; PLACEBO; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ADULT; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; ILEUS; INJECTION SITE REACTION; JAPANESE (PEOPLE); LIVER DISEASE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TUBERCULOSIS; DRUG COMBINATION; JAPAN; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; YOUNG ADULT;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84927786112     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.04.012     Document Type: Article

References (19)

1. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
2. Murch S.H., Braegger C.P., Walker-Smith J.A., MacDonald T.T. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34:1705-1709.
3. Murch S.H., Lamkin V.A., Savage M.O., Walker-Smith J.A., MacDonald T.T. Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 1991, 32:913-917.
4. Braegger C.P., Nicholls S., Murch S.H., Stephens S., MacDonald T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339:89-91.
5. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
7. Colombel J.-F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
8. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003, 98:1315-1324.
9. Wu E.Q., Mulani P.M., Yu A.P., Tang J., Pollack P.F. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health 2008, 11:820-829.
10. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
11. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
12. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
13. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.-F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
14. Panaccione R., Colombel J.-F., Sandborn W.J., D'Haens G., Zhou Q., Pollack P.F., et al. Adalimumab maintains remission of Crohn's disease after up to 4years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013, 38:1236-1247.
15. Watanabe M., Hibi T., Lomax K.G., Paulson S.K., Chao J., Alam M.S., et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 2012, 6:160-173.
16. Economou M., Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008, 14:709-720.
17. Panaccione R., Colombel J.-F., Sandborn W.J., Rutgeerts P., D'Haens G.R., Robinson A.M., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 31:1296-1309.
18. Sandborn W.J., Colombel J.-F., Schreiber S., Plevy S.E., Pollack P.F., Robinson A.M., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17:141-151.
19. Cohen R.D. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002, 16:1603-1609.